- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Vertex Pharmaceuticals Inc (VRTX)
Vertex Pharmaceuticals Inc stock price live, this page displays NASDAQ VRTX stock exchange data. View the VRTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Vertex Pharmaceuticals Inc real time stock price chart below.
What Is the Vertex Pharmaceuticals Inc Stock Price Today?
The Vertex Pharmaceuticals Inc stock price today is 491.47.
What Is the Stock Symbol for Vertex Pharmaceuticals Inc?
The stock symbol for Vertex Pharmaceuticals Inc is ""VRTX.""
What Stock Exchange Does Vertex Pharmaceuticals Inc Trade On?
Vertex Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Vertex Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Vertex Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VRTX quote. (ISIN: US92532F1003)
What Is the Vertex Pharmaceuticals Inc Stock Price Today?
The Vertex Pharmaceuticals Inc stock price today is 491.47.
What Is the Stock Symbol for Vertex Pharmaceuticals Inc?
The stock symbol for Vertex Pharmaceuticals Inc is ""VRTX.""
What Stock Exchange Does Vertex Pharmaceuticals Inc Trade On?
Vertex Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Vertex Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Vertex Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VRTX quote. (ISIN: US92532F1003)
Fair Value
An estimate of a Vertex's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
471.65
503.88
52 wk Range
362.50
519.68
Unusual trading volume
1/2
Fair Value
An estimate of a Vertex's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
471.65503.88
52 wk Range
362.50519.68
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VRTX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Vertex's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
517.12
Upside
+5.22%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
8 analysts have revised their earnings downwards for the upcoming period
- Vertex Pharm receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Vertex Pharm receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Vertex Pharm receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Vertex Pharmaceuticals Inc Company Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Vertex Pharmaceuticals Inc SWOT Analysis
Pipeline Powerhouse | Vertex expands beyond cystic fibrosis into pain management and rare diseases, with promising candidates in diabetes and kidney disorders |
Financial Fortitude | Strong revenue growth and raised guidance showcase Vertex's financial health, with analysts projecting continued earnings expansion |
Market Dominance | Explore Vertex's unrivaled position in CF treatment and its strategic entry into the competitive pain management landscape |
Analyst Outlook | Price targets range from $423 to $557, reflecting optimism about Vertex's growth potential and pipeline progress |
Vertex Pharmaceuticals Inc Earnings Call Summary for Q4/2025
- Vertex Pharmaceuticals reported Q4 2025 revenue of $3.2 billion (10% YoY growth), exceeding forecasts, while EPS of $5.03 missed expectations by 0.98%, causing minimal stock impact.
- Cystic fibrosis therapies drove growth with 7% global revenue increase and 11% rise in U.S. sales, while newer products CASGEVY and JOURNAVX contributed significantly to revenue.
- The company projects 2026 revenue between $12.95-13.1 billion (8-9% growth), with over $500 million expected from non-CF products and plans to triple JOURNAVX prescriptions.
- CEO Dr. Reshma Kewalramani outlined 2026 priorities: expanding CF leadership, accelerating CASGEVY adoption, and growing JOURNAVX, positioning Vertex for significant opportunities.
- Despite strong performance, Vertex faces potential challenges including CF market saturation, regulatory hurdles for new approvals, and increased competitive pressures.
Last Updated: 12/02/2026, 23:50
Read Full TranscriptCompare VRTX to Peers and Sector
Metrics to compare | VRTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVRTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 31.6x | 22.2x | −0.5x | |
PEG Ratio | 0.04 | 0.66 | 0.00 | |
Price/Book | 6.7x | 5.0x | 2.6x | |
Price / LTM Sales | 10.4x | 2.6x | 3.3x | |
Upside (Analyst Target) | 7.8% | 10.7% | 47.0% | |
Fair Value Upside | Unlock | 13.8% | 6.1% | Unlock |
Analyst Ratings
23 Buy
6 Hold
2 Sell
Ratings:
31 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 517.12
(+5.22% Upside)
Earnings
Latest Release
Feb 12, 2026
EPS / Forecast
5.03 / 5.08
Revenue / Forecast
3.19B / 3.18B
People Also Watch
FAQ
What Is the Vertex (VRTX) Stock Price Today?
The Vertex stock price today is 491.47.
What Stock Exchange Does Vertex Trade On?
Vertex is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Vertex?
The stock symbol for Vertex is "VRTX."
What Is the Vertex (VRTX) Afterhours Price Today? (Afterhours variable test: 492.32) Current Date: 14 Feb 2026
After hours price: 492.32. After hours price change (units): 0.85. Price change percentage: 0.17%
What Is the Vertex Market Cap?
As of today, Vertex market cap is 124.85B.
What Is Vertex's Earnings Per Share (TTM)?
The Vertex EPS (TTM) is 15.46.
When Is the Next Vertex Earnings Date?
Vertex will release its next earnings report on May 06, 2026.
From a Technical Analysis Perspective, Is VRTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Vertex Stock Split?
Vertex has split 1 times.
How Many Employees Does Vertex Have?
Vertex has 6100 employees.
What is the current trading status of Vertex (VRTX)?
As of 14 Feb 2026, Vertex (VRTX) is trading at a price of 491.47, with a previous close of 465.02. The stock has fluctuated within a day range of 471.65 to 503.88, while its 52-week range spans from 362.50 to 519.68.
What Is Vertex (VRTX) Price Target According to Analysts?
The average 12-month price target for Vertex is USD517.12, with a high estimate of USD625 and a low estimate of USD330. 23 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Buy. The stock has an +5.22% Upside potential.
What Is the VRTX After Hours Price?
VRTX's last after hours stock price is 492.32, the stock has decreased by 0.85, or 0.17%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.